

neuro•fibroma•tosis

Colorado Chapter
P.O. Box 101357
Denver, CO 80250-1357
Phone: (303) 460-8313
Fax: (303) 460-1421

Colorado CTF Contacts

President:
Mark Ebel
Mark.ebel@eyeris.com,
Mark.ebel@alumni.duke.edu
303-734-9942

Secretary:
Kathy Murray
kathy.murray@fiserviss.com
303-750-3645

Treasurer:
Eric Cahn
kevinbcahn@aol.com
303-322-4194

Denver Outreach:
Jane Cahn
janecdenvr@aol.com
303-322-4194

Colorado Springs Outreach:
Dana Stanley
danaapril@aol.com
719-574-1754

Grand Junction Outreach:
Cathy Green
cg79@aol.com
970-257-1260

Monte Vista Outreach:
Susan Carroll
sunsetdreams_03@hotmail.com
719-852-3114

Colorado NF Information Line:
303-460-8313

NF Clinic at The Children's Hospital:
303-724-2370

Adult Genetics Clinic at University
Hospital: 303-493-8333

Children's Tumor Foundation:
www.ctf.org, 800-323-7938



Inaugural Denver
NFWALK
Children's Tumor Foundation

Walking to raise funds
for research to find
treatments and a cure
for neurofibromatosis

Sunday, October 11, 2009
9:00 AM - Check-in/Registration · 10:00 AM - Welcome, Group Picture, Walk Begins

LOCATION
Clement Park
7306 W. Bowles Ave., Littleton, CO
(just two blocks east of Wadsworth Blvd. and Southwest Plaza Mall)

REGISTRATION

Register online at: www.ctf.org/walk

Walkers who raise over \$100 will receive a free T-shirt! Additional shirts may be purchased for \$10 each.

For more information: Mark Ebel at 303-734-9942 or mark.ebel@eyeris.com



There will be entertainment by The Duke Street Kings, light refreshments, a raffle and lots of fun!

If you are in a position to help us underwrite the cost of the Denver Walk, you can make a donation or sponsor the Denver Walk by going to www.ctf.org/walk. Please make checks payable to CTF (memo line: Colorado Chapter) and mail to Colorado Chapter, P.O. Box 101357, Denver, CO 80250-1357.

Attention All Walkers:

The NF Walk represents a great opportunity to get involved with the Children's Tumor Foundation, and to help us reach our goal of raising \$25,000 for NF Research. You can register as an individual walker, or create a team that will walk together. Either way, you will be given a web page link that you can personalize, and then send to your contacts to create awareness of the event and donations on your behalf. There is no registration fee for the NF Walk, and while we hope that you will be motivated to fundraise, we want you to participate in the NF Walk regardless. **Please register today, and we hope to see all of you on October 11th!**

The President's Letter

By Mark Ebel, CTF Colorado Chapter President

This Spring, I was involved in the organization and planning of two very important events sponsored by the Children's Tumor Foundation. Both events were held in Washington D.C. in early April (during the Cherry Blossom Festival), and both events exceeded even my lofty expectations.

The first event was our annual Chapter and Affiliate Council meeting (CAC), which brings together Chapter and Affiliate leadership from across the country. The focus of CAC is on growing and maintaining effective Chapters and Affiliates. CAC serves as a valuable workshop for knowledge transfer, covering topics such as CTF operational and financial updates, research developments, national programs such as the NF Clinic Network, the status of federal lobbying efforts, templates for participation in national fundraising programs, and examples of successful local fundraising and awareness building campaigns. CAC also allows Chapter and Affiliate representatives to meet their counterparts across the country, and serves to energize and motivate this volunteer leadership group. This year, we had a record number of representatives attend CAC, including representatives from several newly formed Affiliates. I completed my term as Chairman of the CAC, and look forward to the direction of our newly elected Chairwoman, Denise Ogle of the Alaska Chapter. Despite these trying economic times, the news from CAC is that the Foundation is healthy, and that there is a great deal of wonderful work being done across the country by CTF volunteers!

The second event was the NF Forum, which attracted over 180 attendees in its inaugural year. CTF staff (Traceann Adams, George Orfanakos, Kim Hunter-Schaedle, Kelly McGowan, Stephanie Yolish and others) were primarily responsible for organizing this event, and they deserve most of the credit for the event's success. The NF Forum represented the Foundation's first attempt to bring together individuals and families from around the country to learn about current NF research efforts, be exposed to the Foundation and its programs, and to meet and interact with CTF staff, with members of the Foundation's national Board of Directors, and with the CAC leadership group. If you are interested, you can find a more detailed summary of the NF Forum and the topics covered during that event on the Foundation's website at www.ctf.org/nfforum.

Feedback from attendees indicated that the NF Forum was a very successful event, including accessible medical presentations from world-renowned NF doctors and researchers, well-organized exposure to the Foundation, its staff and its programs, and the ability to meet and interact with families from all over the US (and even a few outside of the US) who have experienced similar challenges relating to NF. The NF Forum also included a children's program and family-oriented excursions and meals, making it a very family-friendly event. Hopefully, some of you will be interested in attending a future NF Forum!

Back home in Colorado, I am looking forward to our Chapter's First Annual NF Walk, to be held October 11 at Clement Park. We anticipate a fun event, with an easy 5K walk to be followed by a free concert by The Duke Street Kings. We will provide free refreshments, and there is no registration fee to participate. All participants who raise at least \$100 will be given a free commemorative T-shirt, and additional T-shirts will be available for purchase at the Walk. You can find more information about the walk, and a registration form, at www.ctf.org/walk. Please consider inviting all of your friends and family to join us as we endeavor to raise awareness of NF and raise funds for the Children's Tumor Foundation!

Wyoming Writer has NF Connection

Marette and Chuck Nagel of Dubois, Wyoming have two grandsons with NF1. They also own "Saddle Tramps" a store for anything equine. Chuck is a maker of fine saddles and a long-time outfitter with great stories. Marette is a photo journalist who has created a book titled *Wyoming Working Girls: A Tribute to the Extraordinary Women of Wyoming*. The 160 page black and white pictorial book portrays the hardworking, independent, courageous, grit-filled women of Wyoming.

Marette is the contact for CTF Wyoming Affiliate and can be reached at:

Marette Nagel
PO Box 1817
Dubois WY 82513
Phone: (307) 455-2563
Email: wyoingworkinggirls@yahoo.com

Annual Campaign (January 4 – August 10)

\$5 - \$49

Albertsons
Lynne and Scott Anderson
Jeff Baron
Barbara Burrows
Jason and Heidi Herzog
Jerry Johnson
Jeff and Michelle Kroll
Robert McConaughy
Anna Palumbo
David and Veronica Rau
Valerie Refior
Kim and Sheryl Skattum
Silvia Venzor
Eileen Verlie
Camille Zapolsky

\$50 - \$99

John and Eleanor Bowman
Richard Cutler
Charles and Sheryl Griffin
Marilyn Monsma
Frank Romer
Dana Stanley
Ray and Tricia Whyntor

\$100 - \$249

Sean and Trainy Cannon
Steve and Roxann Deutch
Michael and Katharine Dukakis
Marianne Evans
Janet Harris
Fernand Klein
Cynthia Lambrick
Sue Million
Mike and Shelley Pesta
Carol Roman and Robert Kihm
Scott Schmunk
Lindsey Treska
Christopher and Rochelle Victor

\$250 - \$499

Andrea Dukakis and John Hereford
Ruth Stark
United Way

\$500 - \$999

Family and friends of Kevin Cahn
Family and friends of Davis Ebel
Elizabeth Knight

\$4,395

Family and Friends of Jacob Sensenbaugh

When sending your contributions to Colorado CTF or directly to the CTF main offices in New York, please designate "CTF" as the Payee and note "Colorado Chapter" in the memo line.

Thank You!

ALICE 105.9 Annual Fundraiser for TCH Features Frey Family

Sometimes slightly old news is still good news; this story fits into that category. On February 13, 2009, Denver radio station ALICE 105.9 hosted its annual **36 Hours for Kids**. This radio event brought together many people from the Denver community, who have been the beneficiaries of wonderful care at Children's Hospital. These people shared their stories and in turn, the station created a fundraiser for the hospital.

Chapter member Julie Frey had been a regular donor to the ALICE radiothon for several years before the event took on personal significance for her. When the call went out in January for people with experiences at Children's Hospital to participate, she knew she was ready. Not only did she want to encourage others to become annual donors to the hospital but she also wanted to educate people about neurofibromatosis.

Julie has learned a lot about NF. She can explain the lack of function in the tumor suppressor gene in people who have NF, she can explain treatment of symptoms, and she can explain from the heart what it is like to live with constant uncertainty about your child's future. At 6:30 in the morning with NF Clinic Coordinator Kristina Kocsis at her side, Julie touched the hearts of many by sharing two and a half year old daughter Sara's journey with NF. She also reminded Coloradans what a wonderful support network Children's Hospital offers to families facing all types of medical crises.

Sara has a large pelvic plexiform tumor that has required two surgeries to save her kidneys. She has been hospitalized a dozen times for kidney infection or surgery starting in April of 2008; her last hospital stay was 3 weeks long and ended in early June 2009. Other tumors are growing in Sara's right leg and foot and are beginning to form in her left leg.

Sara has received care through the NF Clinic since she was diagnosed at 10 months of age by Dr. Gary Bellus and has



Howie, Erica, Julie, Sara, and B.J.

been a patient of physicians that others know well – Dr. Nick Foreman, neuro-oncology, Dr. Travis Heare, orthopedic oncology, Dr. Ernest Sink, orthopedics, Dr. Peter Furness, urology, and more. Appointments at the hospital are a regular feature in the lives of mom Julie and young Sara. Care for Sara with her new urostomy requires daily nursing from her mom. Julie has quit counting the number of appointments, MRIs, and other procedures that Sara has had.

Though Sara's complex orthopedic and urological needs fill much of Julie's time, she still works full-time as a test technician for Video Accessory Corporation, a company that builds video and audio distribution amplifiers. Julie and Sara live with Julie's mother and step-father and together the adult team helps raise niece and nephew, Brian (6) and Alexis (4), alongside Sara. (For fun Julie shares dinner with friends, reads avidly and keeps abreast of current NF research on the CTF website www.ctf.org.)

ALICE Morning Show DJ's Howie, B.J. and Erica all contributed to Julie's feeling welcomed. Ultimately it was Howie Drummond asking, "How do you do this everyday?" Julie took a deep breath and with confidence and clarity said, "I do this like every other parent. I get up every day and put my pants on one leg at a time. I give Sara meds to make sure her leg doesn't hurt. I do what is required for my daughter to have as happy and as healthy a life as possible." Julie knows she can't change things but she is fully determined to cope and deal with the life in its fullest.

2009 Annual NF Conference in Portland, Oregon

By Kristina Kocsis, MS, CGC,
NF Clinic Coordinator at
The Children's Hospital

In June 2009, I attended the annual CTF medical conference in Portland, Oregon sponsored by the CTF. Historically, the conference has focused on basic research efforts in understanding NF1, NF2 and schwannomatosis through mouse and fly models. Over the past few years, however, the conference has presented more and more information about how these basic research endeavors translate into human clinical trials. Approximately two years ago, the CTF created a Clinical Trials Consortium to better organize and prioritize clinical trial efforts. Decisions were made to prioritize efforts for clinical trial design and approval by treatment of: 1) plexiform neurofibromas 2) low grade optic gliomas 3) learning disabilities 4) malignant peripheral nerve sheath tumors. Since inception of this consortium, clinical trials have either started enrolling patients or will soon enroll patients for treatment of plexiform neurofibromas, low grade optic gliomas and learning disabilities. At this time, data gathered from these clinical trials is either preliminary or not yet available. For MPNSTs, a study was just recently proposed and researchers are hopeful a clinical trial will be devised in the near future.

Additionally, there were several lectures about a newly identified NF1-like syndrome caused by mutations in a gene known as SPRED1. This NF1-like syndrome is now newly named Legius syndrome after Dr. Eric Legius who first identified the gene. Data presented at the conference suggest individuals with Legius syndrome identified thus far only develop café au laits and skin fold freckling; they do not go on to develop neurofibromas or optic gliomas. And while initial reports of individuals with Legius syndrome were thought to have no learning disabilities, data presented at the conference suggest that indeed some children do have learning issues although the learning disabilities are notably milder than those associated with NF1. The exact prevalence of Legius syndrome is not yet known but the few studies presented at the conference estimate it to be approximately 1.5% - 8% of all individuals who meet NF1 clinical criteria with café au laits and freckling. So far, the NF1 clinical diagnostic criteria will remain the same, but there is discussion about changing these criteria at some point given this newly described NF1-like syndrome. Similarly, medical management guidelines for individuals with Legius syndrome are unclear but the general consensus is to keep them on the same management protocol as those individuals with NF1 until this syndrome can be better characterized.

The Portland conference will benefit our efforts at Children's Hospital's NF Clinic.

Drug Treatments on the Horizon

Clinical drug studies in NF

By Susan Toomey, M.S.

This second installment in a series of articles takes a closer look at two drugs being studied for use on tumors primarily found in individuals with neurofibromatosis type 2 (NF2). As mentioned in the initial article, many of the drugs currently being studied are not familiar to the majority of families dealing with NF. The goal of the studies is to introduce drugs that have shown promise as treatments in the neurofibromatosis disorders. While some of these drugs may achieve their potential, others may show that they are not suited to the unique challenges of NF symptoms.

NF2 is characterized by bilateral vestibular schwannomas with associated hearing loss in almost all patients by 30 years of age. Individuals with NF2 may also develop other types of tumors, including meningiomas (a tumor type also occasionally seen in NF1).

Sunitinib

Sunitinib is a FDA approved cancer drug used in the treatment of certain kidney and gastrointestinal cancers. Currently, a phase II drug trial of Sunitinib is underway in patients (with NF2 or NF1) with recurrent or inoperable meningioma. Typically,

treatment for meningiomas involves surgical removal. However, some tumors cannot be completely removed and some will return after surgery; very rarely meningiomas can become malignant.

Sunitinib works by interfering with the multiple pathways that allow tumors to grow and spread. Normally, our bodies' cells grow and divide in a controlled and orderly manner. When cells continue to divide more times than needed, a mass of extra tissue, a tumor, can form. Blood vessel formation in and around a tumor, gives it the nutrients and oxygen needed to continue to grow. Sunitinib has been shown to prevent the formation of new blood vessels, cause cell death, and eventually lead to tumor reduction.

In the on-going phase II drug trial, researchers are studying the effects of Sunitinib on meningiomas that have recurred or are inoperable. The drug is given to the patients orally, followed by imaging studies to document tumor activity. The study will also evaluate the response rate and safety of Sunitinib. For more information regarding this trial see the resources below.

OSU-03012

OSU-03012 is a drug developed at

the Ohio State University and a close structural relative of the drug celecoxib (Celebrex). It has shown potential in the treatment of vestibular schwannomas and malignant schwannomas. Vestibular schwannomas (VS) in NF2 are associated with hearing loss, balance problems, and tinnitus and affect nearly all NF2 patients. Treatment has primarily involved removal via surgical and stereotactic radiosurgical techniques.

The drug OSU-03012 blocks AKT, a biological pathway that prevents cell death leading to unregulated cell growth. Previous studies have shown the drug to cause cell death in several types of cancer cells. In research funded by the Children's Tumor Foundation Drug Discovery Initiative, OSU-03012 was investigated as a potential treatment of schwannomas in mouse models. Results of the mouse studies showed decreased schwannoma growth and thus potential as a drug treatment for vestibular schwannomas and malignant schwannomas in humans.

Per the Children's Tumor Foundation: In 2008 OSU-03012 was licensed to Arno Therapeutics who renamed the drug AR-12. The drug is in early stage clinical trials for glioma and other tumors. Arno has expressed interest in potential application of the drug for NF. Currently, the NF2 mouse studies are continuing at Ohio State University and the researchers are planning toward NF2 clinical trials in collaboration with Arno.

RESOURCES:


More information about the Sunitinib and other trials can be found online at www.clinicaltrials.gov.

The Memorial Sloan-Kettering Cancer Center which is coordinating the Sunitinib study has a web page at www.mskcc.org/mskcc.

Additional information on this and other drug trials for NF can be found at www.ctf.org under the Research tab.

Marathon Team Update

Former Chapter members **Maureen and Jerry Hunter** now live in Seattle and continue their efforts for NF. On June 26, Jerry ran a half-marathon in Seattle to raise money for NF research with his childhood friend, Eric Wagganer. Eric flew in from California for the event. *Running can be an act of love on so many levels!*



Eric Wagganer and Jerry Hunter

Colorado CTF Picnic 2009: Food Fun, and Friends



Crowd enjoys magic and jokes with Bob Larue



Garrison and Davis



Mark, Marilyn and Jeremy



Jennifer and Finn



Colomarco-Calderon Family



Teen girls



Teen boys



Hilarie and Liz



Maldonado Family



Sean, Bob, and Garrison

An Colorado Evening with CTF's Dr. Kim Hunter-Schaedle

By Jennifer Janusz, PsyD.

On April 20, Kim Hunter-Schaedle, Ph.D., the Chief Scientific Officer for CTF, spoke to the Colorado Chapter of CTF at Children's Hospital in Aurora. The audience of thirty-five Coloradans was eager to learn more about the work of the Foundation. Dr. Hunter-Schaedle started by reviewing the mission of CTF: first, to fund and support NF research; second, to provide support and advocacy to those with NF; and third, to inform and increase public awareness of NF.

Research is an important part of the CTF's mission. However, Dr. Hunter-

Schaedle outlined some of the challenges facing researchers focusing on NF. Given the complexity of NF, research must integrate scientists from many different disciplines. Also, every person with NF has different and varying manifestations of the condition, resulting in many areas for research to focus on. However, CTF is committed to funding research with the end goal of developing effective treatments for NF.

CTF has several funding mechanisms to promote such research. These include the Young Investigator Award,

which focuses on initial drug development, the Drug Discovery Initiative, which includes preclinical testing of drugs on cells and animals models, and Early Stage Clinical Trials. Through these mechanisms, CTF is providing funding all along the "pipeline" of drug development and testing, from cells to humans.

There are two large consortium research programs also focused on drug discovery and testing. The NF Preclinical Consortium funded by the Children's Tumor Foundation is a six-center research program focused on testing candidate drugs in multiple NF tumor models. The NF Clinical Trials Consortium funded by the Congressionally Directed Medical Research Program ('DOD') is a nine-center program focused on testing drug effectiveness in humans. They currently have two clinical trials, one assessing the effectiveness of rapamycin in treating plexiform tumors and the other addressing the use of Lovastatin for learning disabilities.

Dr. Hunter-Schaedle also discussed the NF Clinic Network in relation to CTF's goal of providing support, advocacy and public awareness. There are currently 38 CTF-sponsored clinics in the US, with 14 funded coordinators. Through these clinics, over 2800 patients have been seen. By 2011, CTF hopes to have a patient registry and tissue bank, which will help to further improve the care provided to families affected by NF. CTF is committed to supporting excellent care for individuals with NF and they have found that over 90% of patients report being satisfied with the care they received at a clinic. CTF has also been working to provide more information for patients and families on their website and they found that 40% of people found their local clinic through the CTF website. However, CTF not only provides support for people living with NF1, they also provide resources for NF2 and are the only organization specifically funding research in schwannomatosis.

As we know, CTF is a strong organization with an ongoing commitment to the people living with NF1, NF2, and schwannomatosis. Dr. Hunter-Schaedle's talk further emphasized all that CTF does to promote the research and clinical care provided to people with NF.

Chapter Member Presides over Creation and Opening of Crested Butte's Children's Museum

Crested Butte's Trailhead Discovery Museum and Arts Center will officially open in 2010 but the museum sent up a trial balloon from July 3rd to August 2nd this past summer. Kara Miller, Trailhead Board President and Founder, is the visionary for this new western slope endeavor and a member of our Colorado Chapter. The dream of the Trailhead began simultaneously when Sierra, daughter of Kara and Scott Miller was diagnosed with NF 1.



Sierra and brother Nathan love to spend time together in the new "hands on" museum their mom helped create.

It was the fall of 2007 and the idea of a Gunnison County children's museum began to surface among a group of families faced with another long cold winter with young children. Recognizing that there was an overwhelming need for a space for stimulating science projects, art programs, music classes, special kid-friendly events, and an indoor jungle gym, The Trailhead Discovery Museum & Arts Center was born.

To date a number of dedicated volunteers have taken this first concept of a local children's center to the current model of a place of learning and discovery that will have broad-reaching appeal to both local and visiting children. The Trailhead will fulfill the needs of many organizations, families, and individuals who are seeking an engaging, interactive learning environment designed for children to explore and discover their world.

As a member of the national Association for Children's Museums and a federally recognized 501(c)3 organization, The Trailhead is poised to begin its first year of operation with traveling exhibits and programs that will rotate through schools, day-care providers, the Gunnison Community Center, and businesses. Architects and planners are currently working on the final design of the museum space, which will be located at **618 Gothic Avenue** in the town of **Crested Butte**.

"I had the opportunity to make the museum a special place for children and families with NF. I wanted to give something back to the community of which I am now a part and this was how I did it! I felt so supported by people on-line and on the phone whom I had never met following Sierra's diagnosis. . . people I connected with in a way that my other (very caring) friends could not understand," says Kara.

Remember this new venture in the mountains when planning your summer outings for 2010 and remember that the by-laws of the Trailhead Museum state that all children with NF are welcomed at no charge. (Contact Kara if you are planning a trip to Crested Butte. She can be reached at kecamiller@aol.com or 970-349-6525.)

Passages

CELEBRATIONS



Cooper Michael Pesta was born April 15, 2009. He was welcomed by parents Shelley and Mike Pesta and siblings Jeremy, Tristan, and Chloe Ashworth as well as big brother Nathan Pesta. Cooper's mom Shelley is the Colorado Chapter's newest Board member.



Grant Patrick Scrivner was born June 30, 2009. A happy healthy baby with red hair, Patrick is the first child of David and Shannon Scrivner. Shannon worked as a genetic counselor for several years in the NF Clinic until recently changing positions in the Genetics Department at TCH.

Shelaine Hellickson

graduated from Elizabeth High School. Shelaine was diagnosed with NF 2 when she was 10 year old. NF hasn't kept her from pursuing dreams and neither has a 2007 car accident which left her with a broken pelvis.

After recovery from the accident as a high school junior she went around to high schools and middle schools speaking as part of the Alive at 25 program. Her senior year was filled with soccer and maintenance of a 4.0 GPA. Shelaine is grateful her acoustic neuromas are stable and looks forward to attending college this fall.



ADVENTURES AND TRAVELS

Jeremy Ashworth, Sean Ketron and Phillip Servano were the 2009 Colorado NF Campers in Utah. **Henry Schutte** of Colby, Kansas, also a part of the Colorado Chapter, returned to camp via DLA. Two of these young men, Phillip and Henry, are veteran campers and Sean and Jeremy participated in camp for the first time. Ask these teens about their new friends and experiences from their Utah adventures.

Rod Slaght attended two genetics conferences in July. The first was the Mountain States Genetic Foundation in Denver where Rod has contributed for many years as a representative for NF working on wider genetic service delivery. In mid-July Rod attended the annual conference of the Genetic Alliance in Washington D.C. The Alliance has provided a network for genetic support groups for many years and continues to lobby for genetic justice. Rod participated in break-out sessions on leadership, security for genetic information, diagnosing disability through genetic testing as an issue of social justice and more. Rod had the unexpected opportunity to meet Dr. Francis Collins, discoverer of the NF1 gene one evening at a sing-along where Dr. Collins serenaded the group with his guitar. Rod was invited to return to the conference next year and participate in "Hill Day." There he will have the chance, as a health care consumer, to personally meet members of Congress and advocate for needs of people with genetic conditions. Adventures in life continue for Rod with his return to Mexico this winter.

Morighann Weinell, grand-daughter of Judy Rinaldi, attended Easter Seal Camp from June 28th - July 3rd. She had an awesome time and even climbed a rock wall, went on a zip line, rode a horse, went swimming and fishing. She caught two fish!!

Colter, Sydney, and Andrew Carroll enjoyed the 4th of July in the mountains



near their home in Monte Vista. Colter will be in 8th grade this fall, Sydney in 3rd grade and Andrew will be headed to high school.

Ben Mackay traveled to China with the People to People program this summer. This was Ben's third summer traveling internationally with the program.



Jeremy Monsma has recently experienced several challenges including a car accident and a series of hospitalizations. Not to be daunted by those events, Jeremy attended the summer NF picnic

and shared his amazing story of a trip to Nepal two years ago. At that time Jeremy traveled with a local church group to a village near Katmandu where the group painted schools and became friends with villagers. A man of many skills, Jeremy has worked with various recreational groups ranging in age from young children to senior citizens. He has been a runner and a rock climber and all of his skills and interests came to his aid during his adventure in Nepal.

Stephen and Marta Wallin traveled to Poland early in the summer to visit Marta's family and friends. After WW II, Marta's family was resettled from Lvov (now in Ukraine) to the nearby Silesian region of the Książ castle. Książ was built in the thirteenth century and is rich in history; today the castle houses a museum, hotel and a restaurant. Exploring this castle was a pleasure for Marta and Stephen as Marta had never seen the inside of the castle as a child. For Stephen, being in Poland is exciting and challenging because he struggles hearing all conversations clearing (due to a history of acoustic neuroma) and listening to Polish complicates things further. Being open to people and new experiences offsets his uncertainty and he always contributes an uplifting perspective. The trip was a great success.

RETURN SERVICE REQUESTED

EVENT CALENDAR

Inaugural Denver NFWALK: October 11, 2009 – Details, page 1

Are you on the Colorado CTF e-mail database?

Changes on the horizon will soon make our ability to contact you via e-mail even more important.

Send your e-mail address as soon as you read this message to Tom Hattenburg at tomh711@comcast.net and stay in touch!

